Abstract 4260: Molecular imaging of glutamine (Gln) metabolism in RAS wildtype (WT) metastatic colorectal cancer (mCRC)
Jennifer G. Whisenant(Vanderbilt-Ingram Cancer Center), H. Charles Manning(The University of Texas MD Anderson Cancer Center), Dana B. Cardin(Vanderbilt University Medical Center), Gregory D. Ayers(Vanderbilt University), Adria Payne(Vanderbilt University), Jordan Berlin(Dana-Farber Cancer Institute), Robert J. Coffey(Vanderbilt University), Kristen K. Ciombor(Vanderbilt University Medical Center), Tiffany L. Hickman(Vanderbilt University), Satya Das(AstraZeneca (United States)), Laura W. Goff(Vanderbilt University Medical Center), Gary T. Smith(VA Tennessee Valley Healthcare System), Anna Fisher(Sandia National Laboratories California), Allison S. Cohen(Washington University in St. Louis), Cathy Eng(Vanderbilt University)
Cited by 4
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Hepatobiliary Cancers
|Journal of the National Comprehensive Cancer Network|2009|2.3k
Proteogenomic characterization of human colon and rectal cancer
|Nature|2014|1.6k
Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|998
Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|846